Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0239946 (
liver fibrosis
)
8,268
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In chronic hepatitis B virus (HBV) infection, inflammation-associated cytokines including proinflammatory cytokines are involved in the development and progression of
liver fibrosis
. The liver is a source of many cytokines that may influence liver function.
High-mobility group box 1
(
HMGB1
) was identified as an inflammatory cytokine.
HMGB1
is present in nuclei of all mammalian cells and is released both through active secretion from various cells and by passive release from necrotic cells. Here we explore the relationship between
HMGB1
plasma levels and
liver fibrosis
.
HMGB1
serum levels, HBV-DNA, and ALT values were significantly higher in patients with chronic HBV than in controls. In addition,
HMGB1
serum levels were significantly higher in patients with low fibrosis (fibrosis score 1-2) compared to those with high fibrosis (fibrosis score 3-4). In the present study, we have shown that
HMGB1
is a noninvasive, repeatable, and convenient marker for distinguishing advanced fibrosis from low fibrosis in chronic HBV patients. We believe that the inhibition of
HMGB1
may reduce inflammation, apoptosis, and fibrosis, and may stop the progression of chronic liver disease. Furthermore, we are of the opinion that fibrotic progression in chronic liver patients may be prevented by the inhibition of
HMGB1
, and that this substance can be a new means of following chronic HBV treatment.
...
PMID:Is HMGB1 a new indirect marker for revealing fibrosis in chronic hepatitis and a new therapeutic target in treatment? 2114 49
High-mobility group box 1
(
HMGB1
) is originally identified as a DNA-binding protein that functions as a structural co-factor critical for proper transcriptional regulation in somatic cells. Recent studies indicate that
HMGB1
can be passively released from necrotic cells or actively secreted into the extracellular milieu under appropriate signal stimulation. Extracellular
HMGB1
is a multifunctional cytokine that contributes to the process of infection, injury, inflammation, apoptosis, and immune responses by binding to specific cell-surface receptors. Recently, emerging studies indicate that
HMGB1
is closely involved in fibrotic disorders including cystic fibrosis,
liver fibrosis
and pulmonary fibrosis, while
HMGB1
signal inhibitions protect against the experimental models of fibrotic diseases. From a clinical perspective,
HMGB1
represents a current challenge that can be exploited orchestrate reparative responses. This review focuses on the crucial role of
HMGB1
in the pathogenesis of fibrotic diseases and inhibition of which may represent a promising clinical approach for treating tissue fibrosis.
...
PMID:Emerging role of HMGB1 in fibrotic diseases. 2528 57
High-mobility group box 1
(
HMGB1
) is a highly abundant DNA-binding protein that can relocate to the cytosol or undergo extracellular release during cellular stress or death.
HMGB1
has a functional versatility depending on its cellular location. While intracellular
HMGB1
is important for DNA structure maintenance, gene expression, and autophagy induction, extracellular
HMGB1
acts as a damage-associated molecular pattern (DAMP) molecule to alert the host of damage by triggering immune responses. The biological function of
HMGB1
is mediated by multiple receptors, including the receptor for advanced glycation end products (RAGE) and Toll-like receptors (TLRs), which are expressed in different hepatic cells. Activation of
HMGB1
and downstream signaling pathways are contributing factors in the pathogenesis of non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), and drug-induced liver injury (DILI), each of which involves sterile inflammation,
liver fibrosis
, ductular reaction, and hepatic tumorigenesis. In this review, we will discuss the critical role of
HMGB1
in these pathogenic contexts and propose
HMGB1
as a bona fide and targetable DAMP in the setting of common liver diseases.
...
PMID:Role of High-Mobility Group Box-1 in Liver Pathogenesis. 3173 54